Novo Nord18 introduces weekly insulin pen for diabetes treatment in India
Novo Nordisk has launched Awiqli, a basal insulin that allows patients to receive injections once a week rather than every day. The product is sold in disposable pens containing 700 units of medication.
Amalgamated from Livemint (opens in new tab), News18 (opens in new tab)
Novo Nordisk India has introduced Awiqli, a basal insulin treatment designed to allow patients to receive injections on a weekly basis instead of daily. The company announced the launch as its first once-weekly option for diabetes management in the Indian market.
According to reporting from Livemint, the introduction of Awiqli targets a large demographic, with more than 101 million people in India currently living with diabetes. The product aims to simplify treatment by reducing the frequency of injections required for managing the condition.
The medication is administered through a disposable FlexTouch pen. News18 reports that each pen contains 700 units and will be priced at Rs 2,611. This price point equates to approximately Rs 3.70 per unit of insulin.
Why this matters
The launch provides an alternative for a large portion of the Indian population living with diabetes. By moving from daily to weekly injections, the treatment may improve convenience and patient adherence to long-term health management.
What's confirmed / what isn't
Both news outlets confirm the launch of Awiqli as a weekly basal insulin option in India and its availability via a disposable pen. News18 specifically reports the unit count and pricing details.
Background
Basal insulin is a long-acting medication used by people with diabetes to maintain consistent blood sugar levels throughout the day and night. Novo Nordisk is one of the world's largest manufacturers of insulin products.